Evvy raises $40M Series B for vaginal microbiome sequencing

Evvy announced a $40 million Series B led by Catalio Capital Management on Sept. 15, 2026. Founded in 2021, the company sells an at-home test that sequences all vaginal microbes, a method called metagenomic sequencing. It reports serving over 100,000 U.S. patients through 3,000 practitioners. New investors include U.S. Fertility Innovation Fund, Rethink Impact and Muse Capital.